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Background to Research 
Methadone maintenance treatment (MMT) has been available in Ireland since 1992, with initial 
provision of treatment in Dublin. The Report of the Expert Group on the Establishment of a 
Protocol for the Prescribing of Methadone was undertaken in 1993. In 1998, the Misuse of 
Drugs (Supervision of Prescription and Supply of Methadone) Regulations was introduced, with 
specific administrative structures implemented in order to monitor treatment delivery and patient 
trends (Central Treatment List or CTL). The Methadone Treatment Protocol was devised by the 
Irish College of General Practitioners (ICGP) in 1998, in order to present systematic protocols 
for methadone prescription and patient management, support MMT delivery across Ireland, 
general practitioner (GP) training, increase the number of clients on MMT within a community 
based primary care context, and assist in audits (Butler, 2002). An internal review was 
conducted in 2005 by the Methadone Prescribing Implementation Committee (2005). Currently, 
there are three types MMT service provision in Ireland namely; in specialised clinics, and with 
Level 1 and 2 trained prescribing doctors. Level 2 trained doctors are qualified to initiate 
treatment, stabilise doses and provide ongoing maintenance treatment (Delargy, 2008). Level 1 
trained doctors are restricted to 15 patients, with patient stabilisation occurring in specialised 
clinics or with a Level 2 trained doctor. The number of Level 1 doctors has increased grown 
from 151 in 2002 to 218 in 2009. However, less than 5% of patients in Level 2 practice were 
transferred to level 1 doctors per year over the period 2002 to 2009. Most recent data indicates 
that in 2008, 259 Irish doctors provided MMT, with 2/3 of MMT clients treated in specialised 
clinics and 1/3 treated in the community (Health Service Executive, 2011).   
 
The first external review of the Methadone Treatment Protocol was undertaken in 2010, so as to 
maximize treatment provision, assess clinical governance and audit, referral pathways, doctor 
enrollment, training (Level 1 and 2) and coordination, appropriateness and efficacy of urine 
testing, data collection and analysis and engagement with the Department of Justice on 
methadone prescribing in Garda stations was published in December 2010 (Farrell and Barry, 
2010). The review commented on improved prescribing and quality of independent practitioner 
practice, and advised the need to maximize treatment provision and referral pathways with 
requests for detoxification reviewed as part of a service audit process and with a timely 
response (see ‘National Drugs Rehabilitation Framework’ Working group on drugs rehabilitation, 
2007), rural service development, improved integration between and among services, improved 
clinical governance and audit ( see ‘Achieving Excellence in Clinical Governance: towards a 
culture of accountability, 2010), a need to review benzodiazepine prescribing (see ‘Report of the 
Benzodiazepine Committee’ Department of Health and Children 2002), changing urine analysis 
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regimes, Garda prescribing of methadone in stations, expansion of the number of Level 
2doctors with greater emphasis on moving patients from Level 1 to Level 2 doctors. Farrell and 
Barry also commented on the inclusion of burprenorphine and naloxone treatment modalities, 
and to revise the title to “The Opioid Treatment Protocol”.   
 
The research consisted of two distinct phases with Phase One representing CE scheme 
participant views on client concerns relating to informed decision-making around MMT, patient-
doctor relations, long term MMT and efforts directed at tapering methadone dosages, 
detoxification and rehabilitation. This Phase One report (Van Hout and Bingham, 2011) 
concluded by underscoring the need to explore the attitudes and experiences of MMT treatment 
provision from the prescribing doctors’ perspectives in Phase Two.   
 
Methodology 
Qualitative methodology using semi structured in depth interviews was selected in order to fully 
explore the topic of MMT with prescribing doctors in a variety of settings. Ethical approval for 
the study was granted by Waterford Institute of Technology, Ireland in 2011. Semi structured 
interviews were conducted with a snow sample of methadone prescribing doctors (n=16) willing 
to partake in the study in Dublin. The ICGP and the Methadone Implementation Protocol 
Committee were unable to assist in recruitment of participants. 38 doctors were invited to 
partake. 2 doctors declined to partake and 20 did not respond to email and telephone 
messages. The researchers did not offer the doctors an incentive (i.e financial or CME) for 
participation. Each participant was informed as to the research aims, objectives and procedures 
prior to participation in the interviews. Fieldwork for the study commenced in November 2011, 
following an email containing information and consent protocols for each participant. All 
participants gave written consent, were assured of anonymity and allowed to withdraw if and 
when they wished. Audio recordings of the interviews were destroyed following transcription of 
narratives. All transcripts were stored in a locked cabinet and password protected computer at 
WIT. When data saturation was reached, recruitment of participants ceased.   
 
The participants were interviewed using an interview guide developed from issues identified in 
the literature, and contained the following key themes; perception and knowledge of problematic 
alcohol and drug use in their practice, attitudes toward drug misuse as societal versus medical 
issue, attitudes to MMT, issues regarding MMT provision in their practice, confidence in ability 
to provide quality MMT, gaps in MMT service supports, attitudes to shared treatment care 
approaches, relationships with MMT patients, opinions on methadone dosages and tapering, 
patients continuing heroin and other drug use, licit drug prescribing, minors dependent on 
opiates, and identified MMT training needs. The interview guide was piloted with 4 prescribing 
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doctors in another area prior to the main study. Interviews were conducted at a pre arranged 
time with the participants, with all interviews audio recorded with permission. Each interview 
was undertaken using a conversational tone and began by asking the participants to provide 
their initial opinions on MMT prior to use of the semi structured interview guide.  Interviews 
lasted between 45 and 70 minutes, with a mean length of 50 minutes.   
 
The data was analysed with assistance form NVivo 8, a qualitative content analysis software 
package. Interviews were transcribed shortly after each interview and were supported by 
reflective researcher field notes and memos. A simple thematic analysis was conducted 
(Krippendorf, 2004). Each transcribe was read and reread several times by both members of 
the researcher, which assisted in the identification of coded categories, interpretation of data 
and in the explanation of any data outliers. Six major themes were identified from the data.   
 
Results 
Ten Level 2 prescribing doctors and six Level 1 prescribing doctors were interviewed, of which 
five operated in both specialised clinics and private practice, three worked only in specialised 
clinics, and seven were in private practice. Three participants described situations where they 
were certified as Level 1 in their private practices, but were operating as Level 2 in specialised 
clinics.  All participants described working closely with local pharmacists. 
 
Theme One: Viewpoints relating to opiate dependency and MMT 
Several participants described the interplay between genetic predisposition to addiction, drug 
availability and socio economic environmental factors in the form of poverty, unemployment, 
marginalisation, family history of problematic substance use, childhood trauma, early school 
leaving, peer drug use, and personality factors, which were observed to contribute to the 
escalation of opiate and other drug addiction, negative health consequences and criminal 
activity. All participants described opiate dependency as a bio psycho social issue, but observed 
that the current approach to treating opiate dependence was confined to the medical approach, 
despite the recognition of a multiplicity of personality, social and psychological influences on 
addiction and recovery. They highlighted the need to recognise both the pharmacological and 
psychosocial complexities of opiate addiction and the need to treat using combined approaches. 
Many participants described MMT as essentially a successful medical and harm reducing 
treatment approach to addressing opiate dependence and harmful injecting drug use, and that it 
is supported with a strong evidence base. However, medical implications relating to blood borne 
virus (BBV) transmission (Hepatitis C, HIV), infection from injecting drug use, and co occurring 
psychiatric illness were described.   
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All participants observed that MMT offers patients the opportunity to lead a (semi) normal 
lifestyle, but described negative abstinence focused opinions around MMT amongst some 
community based services and also the general public. Whilst offering the patient some 
normality in daily life, and the relinquishing of prior addictive behaviours, all participants 
described MMT as restricting patient freedom. Examples included remembering to take the 
methadone dose every day, going to the pharmacy at least every week, having to attend the 
doctor for prescriptions and urine screening, and planning ahead for holidays. Several 
participants described issues relating to the long term maintenance of patients with MMT, the 
tapering of methadone dosage and the chronic nature of relapse.  
 
Theme Two: Alcohol, illicit and licit drug use in MMT patients 
When questioned with regard to the area characteristics and social consequences of drug and 
alcohol use, a majority of participants described working in deprived and marginalised urban 
areas characterised by high rates of problematic drug and alcohol use. Some participants 
observed that drug education in schools appeared lacking in their areas, and contributed youth 
drug experimentation, pathways toward serious forms of drug use, opiate dependencies and 
destructive social consequences.   
 
Alcohol was observed to be of most concern given its effect on methadone metabolism, 
increased risk for overdose, and potential addiction displacement. The majority of participants 
stated that excessive alcohol consumption, and alcohol dependency was common amongst 
their patients, with some participants estimating that 25-40% of their patients were misusing 
alcohol. Some made comments around the Irish drinking culture, and the potential normalisation 
of irresponsible drinking of alcohol among youth and adults.   
 
Participants in some cases appeared restricted to the substitution treatment of opiate 
dependence via MMT, and described difficulties in treating alcohol misuse. Many participants 
observed that problematic alcohol use was a draw on their resources in managing substitution 
treatment, and in some cases were unable to test for alcohol use due to lack of provision of 
breathalyzers. One participant described concerns for over dose risk in patients misusing 
alcohol whilst in MMT, and increased rates of MMT patient mortality in older individuals, due to 
problematic alcohol use. Several reported concerns for the lack of specific alcohol treatment 
pathways and adjunct counseling services for MMT patients misusing alcohol.   
 
Patient poly drug taking whilst engaging in MMT was mentioned by several participants, and 
included drugs such as cocaine, cannabis, amphetamine, ecstasy, street and prescribed 
benzodiazepines, new psychoactive substances and heroin. In particular, the emergence of 
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new psychoactive substances such as keto amphetamines (mephedrone) and synthetic 
cannabinoids available from headshops
1
 prior to legislative controls, and subsequent availability 
on the street thereafter was observed to create difficulties, due to the lack of available screening 
mechanisms and clinical information available.   
 
Participant views on continued opiate, other drug and alcohol use whilst in MMT were mixed, 
with some participants accepting of continued licit and illicit drug use whilst on methadone, and 
others strongly opposed to supplying methadone (particularly takeaways) in these 
circumstances. Several participants described opiate screening difficulties in distinguishing the 
frequent heroin user from the occasional heroin user, and additionally distinguishing potential 
harms associated with the injecting versus smoking of heroin.   
 
Continued dialogue between doctor and patients was viewed as paramount in reducing harm 
associated with continued heroin injecting, smoking and the use of other substances. 
Participants described dealing with positive opiate urine screens by increasing methadone 
dosage to try and keep patients from using heroin, probing their patients about discontinuing the 
programme, and working towards a harm reduction dose. MMT patients were observed in some 
cases to ‘simply give up heroin’ over time.   
 
When questioned around the use and misuse of licit drugs, some participants described the 
prescribing of benzodiazepines (‘benzos’) as problematic, and in most cases not initiated by the 
doctor in question. Examples included the use of street benzodiazepines, prescribing by prison 
doctors and in the case of Level 1 private practice, by specialized clinics during stabilization 
periods. Participant concerns centred on difficulties in controlling their patients’ use of 
benzodiazepines, and the potential for development of benzodiazepine dependency. Most 
participants assisted their own patients in undertaking lengthy and gradual benzodiazepine 
detoxes. Several participants also described prescribing SSRIs.  
 
Theme Three: The Methadone Protocols  
The majority of participants observed difficulties in the prescribing of methadone as per the 
National Methadone Protocols as advised by the methadone implementation protocol 
committee. Many described these protocols and related audits as 'big brother looking over you’, 
and reported conflict between the protocols, and real life practice. Issues in the auditing of 
                                                 
1
 A head shop is a retail outlet which specialises in drug paraphernalia related to consumption of cannabis, other 
recreational drugs, and New Age herbs, as well as counterculture art, magazines, music, clothing and home decor. 
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prescribing doctors, doctor adherence and non adherence to the protocols, variation in doctor 
approaches to MMT, and levels of patient centredness in the MMT treatment pathway were 
mentioned.   
 
Despite the protocols in guiding MMT, some participants described the autonomy of doctor 
management of MMT as impacting negatively on parity of treatment and prescribing 
approaches, with some patients observed to be inappropriately managed. Several participants 
described ignoring the Methadone Protocols or not reading them, and adapting the protocols to 
suit their practices. Several participants described the methadone protocols as a policing 
system rather than therapeutic intervention for opiate dependents, with little evidence consulted 
in the design of specified guidelines or the evaluation of individual outcomes. The requirement 
for regular patient urine screening was observed by most participants to be degrading and 
unnecessary. The management of methadone prescribing was observed to be restrictive and 
related to the 7 day methadone prescription pads provided by the Methadone Protocol.  
 
Several participants commented that the Methadone Protocols placed unnecessary and 
unwanted restrictions on MMT patient numbers and their freedom to prescribe as normal 
doctors, particularly in the case of prescribing doctors placed in addiction clinic settings, as 
opposed to doctors operating in general practice. These caps on patient numbers and 
regulations around methadone prescribing at Level 1 and 2 also appeared to restrict numbers of 
treatment places.  
 
The Methadone Protocols were observed by some participants to contribute to patient 
institutionalisation, and in some instance an unequal, punitive doctor-patient relationship. Some 
participants stated that a political cap had been put on estimations of safe methadone dosage 
amid fears around methadone takeaway measures. In general, participants described aiming to 
keep the methadone level safely between 60 and 80mls, in order to avoid potential for overdose 
and cardiac arrhythmias. Some practices had developed specific and improved screening and 
monitoring procedures involving ECGs. Participants described adjusting dosage in order to 
avoid potential methadone diversion (onto the streets) and the continued use of heroin. Several 
participants described how their patients were fearful of heroin withdrawals, and how this 
manifested in a phobic fear of reducing methadone down to too low a dose.   
 
All participants observed that levels of methadone dosage were dictated by the patient’s wishes 
with support from established doctor-patient collaborative work within the therapeutic alliance.  
ne participant described less concern for overdose risk in heroin smokers, than injecting drug 
users. Only in the case of psychiatric disorder, underlying health condition (i.e. HIV) or other 
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drug dependencies (i.e. alcohol, benzodiazepines) would the doctor take control and dictate 
methadone dosage.    
 
Levels of patient methadone dosage were also observed to contradict with community 
employment (CE) scheme entry guidelines, with some participants stating that patients were 
reducing in order to get accepted onto local CE schemes. Others commented on the operation 
of CE Schemes as ‘cherrypicking’ patients who had stabilised, were reducing methadone 
dosages, and who were detoxing. This was observed to impact negatively on the patient 
progress for excluded individuals.  
 
Theme Four: The Doctor -Patient relationship 
The majority of participants described that the doctor patient relationship differed from normal 
general practice due to the weekly contact with their patients, variance in levels of patient 
cooperation, and varying degrees of positive therapeutic alliance. No participants distinguished 
MMT patients from other patients attending their practices, but some participants described 
MMT patients as ‘difficult to deal with’ at times. Issues relating to mistrust, control and 
sanctioning (in some instances) were observed to form the basis for the MMT based doctor 
patient relationship, and appeared related to the patient stage of stabilisation and recovery. 
Many participants described positive relationships encompassing supportive roles with their 
patients and within a regular routine of consultations. Some participants observed that their role 
was restricted to methadone prescribing and the social consequences of opiate dependence, 
with some patients seeing their own GPs for other general health concerns.   
 
Theme Five: MMT Treatment Care Planning 
Collaboration in treatment care planning between the doctor and patients was underscored by 
all participants, despite observations around the restrictions of methadone prescribing and 
necessity for patients to attend the doctor weekly. Patient empowerment in recovery was 
deemed an ultimate goal. A continuum of patient self actualisation was described. Participants 
were described as controlling the starting dose, and the rate of increase, with patients 
controlling a slow tapering and final detoxification under doctor supervision and advice. In all 
instances, client requests to reduce or increase methadone were heard and facilitated within a 
supportive patient led approach, and when stable social circumstances such as housing were in 
place. This was done in order to avoid potential destabilisation and overdose risk. Mixed 
feelings were recorded, with some participants describing reluctance to encourage full 
detoxification, due to the high rates of relapse, and others encouraging full patient detoxification, 
and rehabilitation.   
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All participants described instances of successful patient detoxification from methadone, but 
also observed patients reducing to 40mls or less, and then destabilizing. The revolving door of 
relapse and MMT uptake was common, particularly among young dependents attempting fast 
reduction of methadone, in some instances resulting in high rates of mortality. Some 
participants described a need for community detoxification ‘in the real world’ and observed the 
small success rates recorded in inpatient settings. Several participants described experiences 
of patient self detoxification at home, and observed how improved community detoxification 
protocols were effective in providing supports for both methadone and benzodiazepine. Despite 
this, many instances of home detoxification led to opiate cravings and withdrawals, with many 
patients recommencing heroin, alcohol and other drug use. Underlying mental health issues 
were also observed to further complicate safe home detoxification. Participants underscored the 
need for improved aftercare ‘safety nets’ supports for both residential detoxification and 
community detoxification.  
 
All participants were of the view that shared care treatment approaches in Ireland were much 
needed and essential.  Others described the difficulties of classification as Level 1 or Level 2 as 
difficult to implement in practice, and particularly given the nature of relapse where unstable 
patients necessitate greater levels of support within an interagency support network. Some 
participants described the need for universal and all encompassing treatment services and the 
need for a shift away from strict MMT and toward community based treatment for alcohol, opiate 
and mental health. This could potentially increase treatment uptake and remove the stigma 
attached to clinics. Several participants described the need for alternative forms of opiate 
substitution treatment such as buprenorphine, the need for specialized in patient stabilisation, in 
patient benzodiazepine detoxification, and support structures for those with underlying 
psychiatric conditions. However, several voided concerns around community service 
competencies, level of staff training in the area, and service philosophies around harm reduction 
versus abstinence, and issues around patient confidentiality. Several comments were made 
with regard to service rigidness with regard to patients needs (i.e. location, opening times), and 
the need for development of community nurse prescribers with minor input from doctors.   
 
All participants observed issues relating to minors presenting with opiate dependency, and 
highlighted the need for specialised inpatient detoxification services without the need for 
parental consent and substitution pathways involving a multi disciplinary youth centred 
approach. Many concerns were raised with regard to adolescent treatment readiness and 




Theme Six: MMT Training needs  
Several participants were happy with MMT training levels at the time of the research, and 
indicated no further training needs. Some comments were made about the lack of formal 
training in the addiction field for doctors in clinics and community practice, and the failure of the 
ICGP to provide adequate training, practitioner networking, evidence based protocols, and 
CMEs.  A minority of participants working in private practice described feeling isolated and a 
need to meet and network with practitioners in clinics in order to update and consult around 
MMT issues. Supports for clinical practitioners were described as very good.  
 
Conclusion 
The research, however small scale and exploratory, represents an important description of 
prescribing doctors experiences of MMT in Dublin. Observations around MMT were positive in 
both reducing harm and presenting an important turning point for opiate dependents. It is 
important to underscore that doctor efforts to assist their MMT clients were grounded in positive, 
empathic relationships with their patients, and in many cases surpassed their roles as 
methadone prescribers. The researchers wish to sincerely thank the participants for their 
involvement in the research, and recognise that the findings cannot be representational of all 
prescribing doctors in Ireland. Concerns are evident with regard to the impact of the National 
Methadone Protocols, on two levels, namely the preoccupation with the methadone prescribing 
process as opposed to outcomes, and the restrictions imposed on both Level 1 doctors, and the 
number of resulting treatment places available. Policy makers would be advised to consider the 
expansion of MMT provision to include alternative substitution drugs, improved interagency 
psychosocial supports and the development of a network of community nurse prescribers.  
Additional concerns remain in the form of alcohol and poly drug taking, and pervasiveness of 
benzodiazepine misuse.  Community detoxification protocols must continue to be implemented 
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Chapter 1. Background to Research  
 
Methadone maintenance treatment (MMT) has been available in Ireland since 1992, with initial provision 
of treatment in Dublin. The Report of the Expert Group on the Establishment of a Protocol for the 
Prescribing of Methadone was undertaken in 1993. In 1998, the Misuse of Drugs (Supervision of 
Prescription and Supply of Methadone) Regulations was introduced, with specific administrative 
structures implemented in order to monitor treatment delivery and patient trends (Central Treatment List 
or CTL). The Methadone Treatment Protocol was devised by the Irish College of General Practitioners 
(ICGP) in 1998, in order to present systematic protocols for methadone prescription and patient 
management, support MMT delivery across Ireland, general practitioner (GP) training, increase the 
number of clients on MMT within a community based primary care context, and assist in audits (Butler, 
2002). An internal review was conducted in 2005 by the Methadone Prescribing Implementation 
Committee (2005). Currently, there are three types MMT service provision in Ireland namely; in 
specialised clinics, and with Level 1 and 2 trained prescribing doctors. Level 2 trained doctors are 
qualified to initiate treatment, stabilize doses and provide ongoing maintenance treatment (Delargy, 
2008). Level 1 trained doctors are restricted to 15 patients, with patient stabilization occurring in 
specialised clinics or with a Level 2 trained doctor. The number of Level 1 doctors has increased grown 
from 151 in 2002 to 218 in 2009. However, less than 5% of patients in Level 2 practice were transferred 
to level 1 doctors per year over the period 2002 to 2009. Most recent data indicates that in 2008, 259 Irish 
doctors provided MMT, with 2/3 of MMT clients treated in specialised clinics and 1/3 treated in the 
community (Health Service Executive, 2011).  
 
The first external review of the Methadone Treatment Protocol was undertaken in 2010, so as to 
maximize treatment provision, assess clinical governance and audit, referral pathways, doctor enrollment, 
training (Level 1 and 2) and coordination, appropriateness and efficacy of urine testing, data collection 
and analysis and engagement with the Department of Justice on methadone prescribing in Garda stations 
was published in December 2010 (Farrell and Barry, 2010). The review commented on improved 
prescribing and quality of independent practitioner practice, and advised the need to maximize treatment 
provision and referral pathways with requests for detoxification reviewed as part of a service audit 
process and with a timely response (see ‘National Drugs Rehabilitation Framework’ Working group on 
drugs rehabilitation, 2007), rural service development, improved integration between and among services, 
improved clinical governance and audit ( see ‘Achieving Excellence in Clinical Governance: towards a 
culture of accountability, 2010), a need to review benzodiazepine prescribing (see ‘Report of the 
Benzodiazepine Committee’ Department of Health and Children 2002), changing urine analysis regimes, 
Garda prescribing of methadone in stations, expansion of the number of Level 2doctors with greater 
emphasis on moving patients from Level 1 to Level 2 doctors. Farrell and Barry also commented on the 
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inclusion of burprenorphine and naloxone treatment modalities, and to revise the title to “The Opioid 
Treatment Protocol”.   
 
MMT has long been recognised as an effective treatment for heroin dependence (Amato et al., 2005; 
Clausen et al., 2008). In short, MMT has been evaluated with regard to its efficacy in reducing heroin and 
other forms of substance use, reducing risk behaviours associated with injecting drug use and the 
transmission of blood borne viruses such as HIV and Hepatitis, reducing criminal activity and overdoses 
(Mattick et al., 2009; Corsi et al., 2009; Coviello et al., 2011). Other improvements in MMT client individual 
and social functioning relate to family relationships, employment, education and community integration 
(Corsi et al., 2009; De Maeyer et al., 2011; Coviello et al., 2011; Van Hout and Bingham, 2011). MMT is 
not without problems, and most particularly in terms of organization of the treatment and stigma relating 
to its use which has restricted its uptake, its efficacy, relationships with treatment providers, treatment 
retention and optimum MMT service provision (Joseph et al., 2000; Bell et al., 2002; Van Hout and 
Bingham, 2011; Harris and McElrath, 2012). A great variation of health professional attitudes toward MMT 
and treatment outcomes exists (Gjersing et al; 2010; Lloyd, 2010). Commentaries have discussed MMT’s 
problems as grounded in its status as ‘non treatment’ where one drug is essentially replaced by another, 
and its challenge of abstinence focused ideologies (Lloyd, 2010). Research has underscored the 
presence of public, institutional and private stigma associated with MMT on the part of patients 
themselves, health professionals, pharmacy settings and the general public (Luoma et al., 2007; Ormston 
et al., 2010; Harris and McElrath, 2012). This serves to contribute to MMT patients’ continued identity as 
‘drug addict  which exposes them as so called ‘undeserving’ customers in the public domain, and 
encourages patients to act as passive recipients of treatment (Harris and McElrath, 2012; Van Hout and 
McElrath, 2012). At best, Harris and McElrath (2012) in their studies on MMT in north and south Ireland, 
observe that MMT in Ireland is best viewed as an intervention rather than a treatment modality, with 
pharmacological aspects to treatment undermined by client service experiences typified by social control. 
Research has commented on conflicting evidence in terms of patient satisfaction with methadone 
prescribing doctors (McLaughlin et al., 2000; Winstock et al., 2011), and experiences of prejudice and 
discrimination (Holt, 2007; Ja¨rvinen, 2008). Indeed, patients with a history of drug use, particularly that of 
heroin may believe doctor attitudes towards them to be negative and prejudicial, which highlights the 
need for recruitment of doctors with positive attitudes towards helping those with drug dependence 
(Gabbay et al., 1996; Abouyanni et al 2000; Kelly and Westerhoff, 2010). According to Dole and 
Nyswander (1980) mutual respect between the MMT client and treatment staff is fundamental to reduce 
perceived structural and interpersonal factors which impact negatively on treatment progression.  
 
The shared care of drug users has been extensively discussed in the literature (Watson, 2000; Abouyanni 
et al., 2000; Langton et al., 2000; Keen, 2001; McKeown et al., 2003). Opiate drug users represent a 
challenge to general practice (Leaver et al., 1992). Indeed, general practice represents the first port of call 
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and main point of contact between drug dependents and medical services and presents a unique 
opportunity to assist early with minimal stigmatisation in comparison to that attached to more formalised 
addiction treatment (Greenwood, 1992; Bucknal et al., 1986). Research indicates that drug users also 
record a preference for the treatment of their dependency within general practice (Bennett and Wright, 
1986). Research shows that shared care incurs many positive effects in terms of increased client 
satisfaction, reductions in crime and other drug use, and uptake in preventative health measures (Wilson 
et al., 1994, Gossop 1997, Gruer et a1 1997; Gabbay et al., 1996). However, reports of high patient 
turnover and consultation time pressures are evident in the MMT literature (Neville et al., 1988). Research 
by Leaver et al., (1992) reported that the methadone prescribing element of MMT is responsible for 
greater numbers of doctor visits and emergency appointments to obtain methadone prescriptions to 
relieve withdrawals. Problematic drug users reportedly consult their general practitioner significantly more 
often than non-drug using patients, and particularly those with HIV infection (Neville, 1988; Robertson, 
1989; Leaver et al., 1992). Research in the UK has reported on successful general practice based MMT 
interventions (Parker and Kirby 1996; Wilson et al., 1994, Gruer et a1 1997; Farre11 and Gerada 1997, 
Scott 1997, Teijlingen and Porter 1997).  
 
Traditionally, general practitioners have reported negative attitudes to methadone prescribing (Glanz and 
Taylor 1986 a; b, Leaver et a1 1992). Prescribing doctor attitudes to MMT are frequently grounded in drug 
use as social manifestation, with medicalised and abstinence based focus (McKeown et al., 2003; Van 
den Brink and Haasen, 2006; Ford and Ryrie, 2010). Some doctors lack interest in the treatment of 
problematic drug use within the context of primary care service provision (Kapadia et al., 2007). This is 
seen to contribute to displacement of stigma from MMT clinic settings and into general practice 
(Matheson et al., 2003). Reluctance is grounded in perceived lack of skills and expertise, workload, 
concerns around safety and aggressive patients, and attitudes to drug users (Langton et al., 2000; 
Abouyanni et al., 2000; McGillion, 2000; Ford and Ryrie 2000; Matheson et al., 2003). Doctor attitudes 
can be particularly negative toward opiate and intravenous drug users as opiate dependent patients often 
present with manipulative, aggressive and chaotic behaviours, with fluctuating levels of motivation 
impacting on the doctor patient therapeutic alliance (Gruer et al., 1997, Gabbay et al., 2001; Butler, 
2002). However, research has reported that newly qualified doctors indicate greater acceptance of 
problematic drug users, and self awareness of their competency to treat dependencies (Glantz and 
Taylor, 1986; Roche et al., 1991; Carnwath et al., 1999). Research on MMT consistently highlights 
training needs in this area (Bell and Zador, 2000; Ford and Ryrie, 2000; Gabbay et al., 2001; Strang et 
al., 2004; Delargy 2008) alongside efforts to reduce health professional negative stereotypical opinions 
and attitudes toward problematic drug users (Miller et al., 2001; Merill et al. 2002; Landy et al. 2005; 
Henderson et al., 2008; Lloyd, 2010; Gjersing et al., 2010).  
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Research has also underscored the need to reframe MMT as treatment modality to view clients in a more 
positive accepting manner as customers or consumers (Luty and Grewal, 2002; Luoma et al., 2007; 
Fraser and Valentine, 2008; Reisinger et al., 2009), and where clients can be organized in a collective 
manner in the form of service user forums so as to create autonomous and inclusive dialogue and 
stakeholder relations between those on MMT and their treatment providers (Patterson et al., 2007; Harris 
and McElrath, 2012, Van Hout and McElrath, 2012 forthcoming). MMT clients are rarely consulted as 
consumer group in Ireland (UISCE, 2003) with emergent attitudinal shifts evident in promoting methadone 
maintenance service user involvement in treatment pathways (King 2011; Van Hout and McElrath, 2012 
forthcoming). Indeed, the Phase One Research Report on perspectives of Special Community 
Employment (SCE) scheme participants on MMT in the Dublin North East Task Force area (Van Hout and 
Bingham, 2011) was based on a partnership between the Task Force and Client Forum representing 
participants of several SCE schemes and used a peer research led approach to discuss (amongst 
themes regarding education and employment) client concerns relating to informed decision-making 
around MMT, patient-doctor relations, long term MMT and efforts directed at tapering methadone 
dosages, detoxification and rehabilitation.  The research concluded by underscoring the need to explore 
the attitudes and experiences of MMT treatment provision from the prescribing doctors’ perspectives in 
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Chapter 2. Methodology 
 
Qualitative methodology using semi structured in depth interviews was selected in order to fully explore 
the topic of MMT with prescribing doctors in a variety of settings. Ethical approval for the study was 
granted by Waterford Institute of Technology, Ireland in 2011.   
 
Participants 
Semi structured interviews were conducted with a snow sample of methadone prescribing doctors (n=16) 
willing to partake in the study in Dublin.  The ICGP and the Methadone Implementation Protocol 
Committee were unable to assist in recruitment of participants. 38 doctors were invited to partake. 2 
doctors declined to partake and 20 did not respond to email and telephone messages. The researchers 
did not offer the doctors an incentive (i.e financial or CME) for participation. Each participant was 
informed as to the research aims, objectives and procedures prior to participation in the interviews. 
Fieldwork for the study commenced in November 2011, following an email containing information and 
consent protocols for each participant. All participants gave written consent, were assured of anonymity 
and allowed to withdraw if and when they wished. Audio recordings of the interviews were destroyed 
following transcription of narratives. All transcripts were stored in a locked cabinet and password 
protected computer at WIT. When data saturation was reached, recruitment of participants ceased.   
 
Interviews 
The participants were interviewed using an interview guide developed from issues identified in the 
literature, and contained the following key themes; perception and knowledge of problematic alcohol and 
drug use in their practice, attitudes toward drug misuse as societal versus medical issue, attitudes to 
MMT, issues regarding MMT provision in their practice, confidence in ability to provide quality MMT, gaps 
in MMT service supports, attitudes to shared treatment care approaches, relationships with MMT patients, 
opinions on methadone dosages and tapering, patients continuing heroin and other drug use, licit drug 
prescribing, minors dependent on opiates, and identified MMT training needs. The interview guide was 
piloted with 4 prescribing doctors in another area prior to the main study. Interviews were conducted at a 
pre arranged time with the participants, with all interviews audio recorded with permission. Each interview 
was undertaken using a conversational tone and began by asking the participants to provide their initial 
opinions on MMT prior to use of the semi structured interview guide.  Interviews lasted between 45 and 
70 minutes, with a mean length of 50 minutes.   
 
Data Analysis 
The data was analysed with assistance form NVivo 8, a qualitative content analysis software package. 
Interviews were transcribed shortly after each interview and were supported by reflective researcher field 
notes and memos. A simple thematic analysis was conducted (Krippendorf, 2004). Each transcribe was 
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read and reread several times by both members of the researcher, which assisted in the identification of 
coded categories, interpretation of data and in the explanation of any data outliers. Six major themes 
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Chapter 3. Results of Narrative Analysis 
 
Ten Level 2 prescribing doctors and six Level 1 prescribing doctors were interviewed, of which five 
operated in both specialised clinics and private practice, three worked only in specialised clinics, and 
seven were in private practice. Three participants described situations where they were certified as Level 
1 in their private practices, but were operating as Level 2 in specialised clinics.  All participants described 
working closely with local pharmacists. Due to confidentiality it is not possible to engage in a gender 
analysis.  
‘In my practice I am Level 1, but I work as Level 2 in the addiction services, it’s ridiculous. I 
am working in the area for over 5 years full time in Level 2, but in my private practice, I am 
Level 1.  Participant 7 
 
Theme One: Viewpoints relating to opiate dependency and MMT 
Several participants described the interplay between genetic predisposition to addiction, drug availability 
and socio economic environmental factors in the form of poverty, unemployment, marginalisation, family 
history of problematic substance use, childhood trauma, early school leaving, peer drug use, and 
personality factors, which were observed to contribute to the escalation of opiate and other drug 
addiction, negative health consequences and criminal activity.   
‘It is multi-factorial.  There is a medical component to addiction, and reward and the 
withdrawals, and that’s dependence…and then social is the availability, social deprivation 
and life events that would lead people to ignore things in their life and turn to drugs and 
alcohol, it’s a combination.’  Participant 10 
All participants described opiate dependency as a bio psycho social issue, but observed that the current 
approach to treating opiate dependence was confined to the medical approach, despite the recognition of 
a multiplicity of personality, social and psychological influences on addiction and recovery. They 
highlighted the need to recognise both the pharmacological and psychosocial complexities of opiate 
addiction and the need to treat using combined approaches.   
‘The drug addiction always had two responses from the community and the professionals.  
The professionals tended to treat it as an isolated medical problem, and the community 
treated as it was meant to be treated, which was a social psychological and a biological 
model.  The problem was that these two sectors didn't work as well as they could, and 
continues to remain a problem.’  Participant 1 
Many participants described MMT as essentially a successful medical and harm reducing treatment 
approach to addressing opiate dependence and harmful injecting drug use, and that it is supported with a 
strong evidence base. However, medical implications relating to blood borne virus (BBV) transmission 
(Hepatitis C, HIV), infection from injecting drug use, and co occurring psychiatric illness were described.   
‘It is fantastic, it is wonderful , it’s a wonderful drug, it has immediate benefits in pretty much 
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every aspect of a person’s life, that have been dysfunctional or impaired in any way, it effects 
every part of their life, it’s just wonderful.’ Participant 6 
‘I am a big supporter, it’s been proven to be a very effective way of dealing with the 
problem… it’s not a cure for the ills of the individual or society that has to deal with it. I am a 
great believer in harm reduction right up to abstinence to clean living.  Methadone 
maintenance is a completely proven modality of treatment.’ Participant 13 
All participants observed that MMT offers patients the opportunity to lead a (semi) normal lifestyle, but 
described negative abstinence focused opinions around MMT amongst some community based services 
and also the general public.   
‘I do support it, for me, my aim is to help the individuals to get to a point, where they are able 
to function reasonably normally in their own lives, to do whatever they feel is normal. 
Methadone Maintenance for a lot of my clients is their goal, if they can get to a point where 
they can function normally in their lives through methadone maintenance, then that’s good 
enough.’ Participant 3 
 ‘People who are on it long term, have a life.  Drug users who aren't on methadone, they 
haven't a hope, they cannot possibly manage their children or do anything at least it allows 
them to lead a semi normal life.’ Participant 2 
Whilst offering the patient some normality in daily life, and the relinquishing of prior addictive behaviours, 
all participants described MMT as restricting patient freedom. Examples included remembering to take the 
methadone dose every day, going to the pharmacy at least every week, having to attend the doctor for 
prescriptions and urine screening, and planning ahead for holidays. 
‘I think it’s great, but a bit limited. I take quite a pragmatic approach. I think if people need to 
stay on methadone for the rest of their lives, in order to be able to live a useful satisfactory 
life, then I have no problem with that.  Methadone is not a cure and they are not free of the 
addiction, so it still limits their lives a lot, the best thing of all, is if we had something that 
would free them of their addiction, and then they could lead a completely normal life, but by 
its very nature its addictive, so you’re dependant on it, you don’t have quite the same 
freedom, as someone who is not dependant on something. ‘Participant 2 
Several participants described issues relating to the long term maintenance of patients with MMT, the 
tapering of methadone dosage and the chronic nature of relapse.  
‘The biggest problem with methadone is getting them off methadone, it’s a bit like using the 
nicotine patches for nicotine, we are aware we need to get them off the patches, but we don’t 
seem to have a handle on this thing, where they should be off the methadone within a 
certain amount of time. I think it’s this fear we have of heroin, that it’s a more addictive drug 
than any other, and it cannot be dealt with like any other addiction.’  Participant 6 
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Theme Two: Alcohol, illicit and licit drug use in MMT patients 
When questioned with regard to the area characteristics and social consequences of drug and alcohol 
use, a majority of participants described working in deprived and marginalised urban areas characterised 
by high rates of problematic drug and alcohol use. Some participants observed that drug education in 
schools appeared lacking in their areas, and contributed youth drug experimentation, pathways toward 
serious forms of drug use, opiate dependencies and destructive social consequences.   
‘I see it as primarily a physical addiction, the consequences are physical. But its social in a 
sense that you would sell your mother to fund it, so you end up losing everything, your 
family, your self respect, your house, your kids and your freedom, ending up in prison if you 
go all the way, which a lot of them do.’ Participant 11 
Alcohol was observed to be of most concern given its effect on methadone metabolism, increased risk for 
overdose, and potential addiction displacement. The majority of participants stated that excessive alcohol 
consumption, and alcohol dependency was common amongst their patients, with some participants 
estimating that 25-40% of their patients were misusing alcohol. Some made comments around the Irish 
drinking culture, and the potential normalisation of irresponsible drinking of alcohol among youth and 
adults.   
It’s an enormous problem, the substance that is killing most of my patients, taking up most of 
my time….significant physical and medical complications, psychological and massive social 
consequences.’ Participant 7 
Participants in some cases appeared restricted to the substitution treatment of opiate dependence via 
MMT, and described difficulties in treating alcohol misuse. Many participants observed that problematic 
alcohol use was a draw on their resources in managing substitution treatment, and in some cases were 
unable to test for alcohol use due to lack of provision of breathalyzers. One participant described 
concerns for over dose risk in patients misusing alcohol whilst in MMT, and increased rates of MMT 
patient mortality in older individuals, due to problematic alcohol use.  
Their alcohol problem would be way above and beyond their drug use problem…it’s the 
biggest cause of death in our slightly older patients, is alcohol and Hepatitis C together.  
They know we are bothered by the use of alcohol and methadone in relation to overdose risk 
because we reduce their methadone.’  Participant 4 
Several reported concerns for the lack of specific alcohol treatment pathways and adjunct counseling 
services for MMT patients misusing alcohol.   
‘A lot of doctors don’t really engage with those who use alcohol, we have precious little to 
offer them… all we have is methadone for heroin users.’ Participant 8 
Patient poly drug taking whilst engaging in MMT was mentioned by several participants, and included 
drugs such as cocaine, cannabis, amphetamine, ecstasy, street and prescribed benzodiazepines, new 
psychoactive substances and heroin. In particular, the emergence of new psychoactive substances such 
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as keto amphetamines (mephedrone) and synthetic cannabinoids available from headshops
1
 prior to 
legislative controls, and subsequent availability on the street thereafter was observed to create difficulties, 
due to the lack of available screening mechanisms and clinical information available.   
 
Participant views on continued opiate, other drug and alcohol use whilst in MMT were mixed, with some 
participants accepting of continued licit and illicit drug use whilst on methadone, and others strongly 
opposed to supplying methadone (particularly takeaways) in these circumstances. Several participants 
described opiate screening difficulties in distinguishing the chaotic heroin user from the occasional heroin 
user, and additionally distinguishing potential harms associated with the injecting versus smoking of 
heroin.   
‘I am always disappointed, but I would always continue to give them their usual methadone 
dose.’ Participant 2 
Continued dialogue between doctor and patients was viewed as paramount in reducing harm associated 
with continued heroin injecting, smoking and the use of other substances. Participants described dealing 
with positive opiate urine screens by increasing methadone dosage to try and keep patients from using 
heroin, probing their patients about discontinuing the programme, and working towards a harm reduction 
dose. MMT patients were observed in some cases to ‘simply give up heroin’ over time.   
‘There cannot be a one attitude in addiction treatment, you must be prepared to take the 
patients where the patient is at, there are many patients who dabble, who become sick and 
tired and then stop, and then come off methadone. I have many patients who were heavy 
users and are now drug free.’ Participant 3 
When questioned around the use and misuse of licit drugs, some participants described the prescribing of 
benzodiazepines (‘benzos’) as problematic, and in most cases not initiated by the doctor in question.  
Examples included the use of street benzodiazepines, prescribing by prison doctors and in the case of 
Level 1 private practice, by specialized clinics during stabilization periods.  Participant concerns centred 
on difficulties in controlling their patients’ use of benzodiazepines, and potential development of 
benzodiazepine dependency.  Most participants assisted their own patients in undertaking lengthy and 
gradual benzodiazepine detoxes. Several participants also described prescribing SSRIs.  
‘I don’t tend to initiate benzos. I do benzo detox's. Benzos are not indicated for anything 
more than short term, and I don’t even believe they are for that. I don’t see any role for 
benzodiazepines in the treatment for an underlying condition, particularly in this cohort of 
patients’. ‘Participant 9 
                                                 
1
 A head shop is a retail outlet which specialises in drug paraphernalia related to consumption of cannabis, other recreational drugs, 
and New Age herbs, as well as counterculture art, magazines, music, clothing and home decor. 
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Theme Three: The Methadone Protocols  
The majority of participants observed difficulties in the prescribing of methadone as per the National 
Methadone Protocols as advised by the methadone implementation protocol committee. Many described 
these protocols and related audits as 'big brother looking over you’, and reported conflict between the 
protocols, and real life practice.  
‘There is a disconnection between the people on the methadone protocol implementation 
committee and people making decision and those who are working on the ground.’ 
Participant 15 
‘The way I am forced to practice with the guidelines being enforced, having this big stick held 
over me, if I don’t practice exactly the way, according to the guidelines which I don’t agree 
with. I must practice in quite a restrictive way which is controlling and disempowering. I am 
subject to an audit and in the audit. I have to prove I am asking for four urines a week and 
change takeaways, if a patient gives a opiate positive urine.’ Participant 2 
Issues in the auditing of prescribing doctors, doctor adherence and non adherence to the protocols, 
variation in doctor approaches to MMT, and levels of patient centredness in the MMT treatment pathway 
were mentioned.   
‘Absolutely the problem with them, is not the actual content of the guidelines, it’s the problem 
how they are enforced, they are enforced, as if they are a standard operating procedure, if 
you make any attempt to go outside of them, you are stamped on.’ Participant 8 
Despite the protocols in guiding MMT, some participants described the autonomy of doctor management 
of MMT as impacting negatively on parity of treatment and prescribing approaches, with some patients 
observed to be inappropriately managed.  
‘I am aware of colleagues practicing differently, being told that they are not getting any more 
patients.’ Participant 2 
Several participants described ignoring the Methadone Protocols or not reading them, and adapting the 
protocols to suit their practices. 
‘In Ireland, nobody obeys the rules to the letter, mostly the protocol is fine, if it was called a 
guideline, I would be happy with it, because guidelines are only expected to be a guideline, 
and as a doctor you are able to adapt that according to the circumstances. I think it would be 
impossible to write a protocol that would be right for everybody as a general guideline.’ 
Participant 2 
‘I tend to ignore them now, some of the protocols are good, some of them would be useful to 
people new to the area. I would interpret these as a guideline. It’s very rare that you find a 
individual patient that fits all guidelines.’ Participant 7 
 
Several participants described the methadone protocols as a policing system rather than therapeutic 
intervention for opiate dependents, with little evidence consulted in the design of specified guidelines or 
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the evaluation of individual outcomes. The requirement for regular patient urine screening was observed 
by most participants to be degrading and unnecessary.   
‘The audit is about process and not about outcomes. This is a glaring failure, it would be so 
much better to audit outcomes.’ Participant 7 
The management of methadone prescribing was observed to be restrictive and related to the 7 day 
methadone prescription pads provided by the Methadone Protocol.  
‘It does need to be managed fairly tightly, there is maybe scope of extending the length of 
prescriptions like in other countries, but the prescription pads that we have for methadone 
that have to be used, they are specifically for seven days treatment, it’s the methadone 
protocol, as set up and approved.’ Participant 5 
Several participants commented that the Methadone Protocols placed unnecessary and unwanted 
restrictions on MMT patient numbers and their freedom to prescribe as normal doctors, particularly in the 
case of prescribing doctors placed in addiction clinic settings, as opposed to doctors operating in general 
practice.   
‘I am not entirely free to prescribe the way I would like to prescribe in any setting.  The 
problem with the protocol, is that is does not help people who would like to open up a 
methadone clinic, whereby someone could set up a clinic in an existing general practice and 
treat patients there without a cap. Because I don’t do anything else then to treat methadone 
patients, the random figures of 25 and 15 for level 2 and level 1, these concepts were meant 
to assist a busy general practitioner and it does assist them, but it works against those who 
are dedicated Methadone prescribers.’ Participant 1   
‘They restrict my private practice, I am Level 1 and there is a restriction on numbers but there 
are people like me who are Level 2 in the clinic and Level 1 in private practice. When they 
say that you cannot initiate your own patients when you’re Level 1, and when you have been 
initiating very chaotic clients in the clinics, then yes, its restrictive and there are a lot like 
me..’ Participant 7 
These caps on patient numbers and regulations around methadone prescribing at Level 1 and 2 also 
appeared to restrict numbers of treatment places.  
‘This prohibits more patients entering treatment than otherwise could be, we could reduce 
many waiting lists and work in community programmes. This is my career. I do nothing than 
other prescribe methadone. However there are too many constraints on me, a lot of the 
constraints have to do with the fact that you need to separate the issue around prescribing in 
a protocol practice with prescribing in a clinic, because there is a multidisciplinary team in the 
clinic. In your general practice, you are relatively free to do what you want, especially if you 
have a good relationship with your community pharmacist.’ Participant 1 
 
The Methadone Protocols were observed by some participants to contribute to patient institutionalisation, 
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and in some instance an unequal, punitive doctor-patient relationship. Some participants stated that a 
political cap had been put on estimations of safe methadone dosage amid fears around methadone 
takeaway measures. In general, participants described aiming to keep the methadone level safely 
between 60 and 80mls, in order to avoid potential for overdose and cardiac arrhythmias. Some practices 
had developed specific and improved screening and monitoring procedures involving ECGs. Participants 
described adjusting dosage in order to avoid potential methadone diversion (onto the streets) and the 
continued use of heroin. Several participants described how their patients were fearful of heroin 
withdrawals, and how this manifested in a phobic fear of reducing methadone down to too low a dose.   
‘There is this huge obsession that the patient should not be on too much methadone 
because if they are on a high level of methadone, they are going to get worse, where in fact 
the exact opposite is the case, if a patient needs a lot of methadone, that is where they are 
at that particular point in time, provided you give them that dosage and continue to work with 
them they will invariably reduce their dosage.’ Participant 1 
All participants observed that levels of methadone dosage were dictated by the patient’s wishes with 
support from established doctor-patient collaborative work within the therapeutic alliance.  One participant 
described less concern for overdose risk in heroin smokers, than injecting drug users. Only in the case of 
psychiatric disorder, underlying health condition (i.e. HIV) or other drug dependencies (i.e. alcohol, 
benzodiazepines) would the doctor take control and dictate methadone dosage.    
‘In principle you would like to them to receive a dose that makes it easier for them to abstain 
from heroin.’ Participant 14 
Levels of patient methadone dosage were also observed to contradict with community employment (CE) 
scheme entry guidelines, with some participants stating that patients were reducing in order to get 
accepted onto local CE schemes. Others commented on the operation of CE Schemes as ‘cherrypicking’ 
patients who had stabilised, were reducing methadone dosages, and who were detoxing. This was 
observed to impact negatively on the patient progress for excluded individuals.  
 
Theme Four: The Doctor -Patient relationship 
The majority of participants described that the doctor patient relationship differed from normal general 
practice due to the weekly contact with their patients, variance in levels of patient cooperation, and 
varying degrees of positive therapeutic alliance.   
‘I have a counselor psychotherapist therapeutic model of alliance with my clients, rather than 
the general practice model of alliance, it’s based on being client centered but with a element 
of control, while I am more than happy to listen to what my clients has to say, what I can 
actually do and give to the patient is dictated by the control element of prescribing a 
controlled drug.’ Participant 1 
‘I am not sure if it would be typical of a GP client relationship in general practice, it’s an 
ongoing relationship, so it’s not quite like a ordinary GP relationship, it can be a bit traumatic 
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and confrontational at times, because there is an element of control with the methadone that 
introduces a different dynamic, so within that you have very good relations with some of the 
patients, middling with others and not great relations with some.’ Participant 4 
No participants distinguished MMT patients from other patients attending their practices, but some 
participants described MMT patients as ‘difficult to deal with’ at times. 
‘I don’t see them as any different to any other patient. I am a doctor, they come into me, they 
tell me what’s wrong with them, what they want. I try and get them to be as honest as 
possible. I need to know as to ensure I am giving them the right treatment, then they can 
make the choice about what they take in terms of treatment.  My primary concern is patient 
safety and then the community safety.’ Participant 13 
Issues relating to mistrust, control and sanctioning (in some instances) were observed to form the basis 
for the MMT based doctor patient relationship, and appeared related to the patient stage of stabilisation 
and recovery.   
‘I try to make it respectful that they respect me and I respect them. I try and give them some 
kind of control about what they are doing. I have a good relationship with them but at the 
back of it, it’s not quite a normal doctor patient relationship. When people are doing well or 
when they are chaotic and have no takeaways and they have nothing to lose, then you can 
have quite an open honest relationship with them, but the most difficult time is when 
someone has been doing well and de stabilises.  So if they have got takeaways and you see 
it going wrong and they don’t want to lose the takeaways, so all trust breaks down then, and 
you cannot believe a word they say and then it becomes more punitive. You are almost like a 
policeman to them, you are doing things they don’t like, which doctors don’t often have to do 
to their patients.’ Participant 2 
Many participants described positive relationships encompassing supportive roles with their patients and 
within a regular routine of consultations. Some participants observed that their role was restricted to 
methadone prescribing and the social consequences of opiate dependence, with some patients seeing 
their own GPs for other general health concerns.   
‘I get on well with them. I find I am a bit of a social worker, bit of a police person, school 
teacher and then a medic. I find that I fill a lot of roles because they trust me.’ Participant 12  
‘Principally the doctor patient relationship is different in that I see them every week. It’s 
different that I only prescribe methadone to them. I am not actually their GP, they have 
another doctor who interestingly would know them less well than I would, but I try and get 
them to keep that normal primary care relationship. As well, I find that I am in a position to be 
asked about a lot of other things which are not medical.’ Participant 5 
 
Theme Five: MMT Treatment Care Planning 
Collaboration in treatment care planning between the doctor and patients was underscored by all 
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participants, despite observations around the restrictions of methadone prescribing and necessity for 
patients to attend the doctor weekly. Patient empowerment in recovery was deemed an ultimate goal. A 
continuum of patient self actualisation was described. Participants were described as controlling the 
starting dose, and the rate of increase, with patients controlling a slow tapering and final detoxification 
under doctor supervision and advice. 
‘It’s a collaborative relationship. The most important thing for me is that I don’t make the 
patient worse. It’s a straight relationship. I don’t fight over urine results, because I have no 
interest in them. I never impede anyone who wants to detox. I know that we get a lot of bad 
press keeping people on methadone. I don’t keep anyone on methadone. I give them my 
opinion, we discuss it and they make a decision. I facilitate their detox because they will do it 
on their own, and it’s better to have me with them than to do it on their own.’ GP Participant 5 
‘They have to reduce slowly. It is like a baby learning to walk.’ Participant 9 
In all instances, client requests to reduce or increase methadone were heard and facilitated within a 
supportive patient led approach, and when stable social circumstances such as housing were in place. 
This was done in order to avoid potential destabilisation and overdose risk. Mixed feelings were recorded, 
with some participants describing reluctance to encourage full detoxification, due to the high rates of 
relapse, and others encouraging full patient detoxification, and rehabilitation.   
‘I will encourage detox as much as I can because I don’t want any of my patients enslaved to 
any institution, medical or pharmaceutical. The sooner they get free, the better, it’s all about 
being ready and able to do that.’ Participant 1 
‘I don’t make anyone take a dose of methadone that they don't want to take.  When I start 
them, I explain to them what our philosophy is on methadone.  So they know where we 
stand.  I explain that we will give them any amount of methadone, they require and that we 
will advise them when they are coming down.  I do state that we don't formally detox people, 
but patients may detox themselves.’ Participant 4 
‘It’s a straight jacket for some in that they are caught and cannot get off the methadone.’ 
Participant 8 
All participants described instances of successful patient detoxification from methadone, but also 
observed patients reducing to 40mls or less, and then destabilizing. The revolving door of relapse and 
MMT uptake was common, particularly among young dependents attempting fast reduction of 
methadone, in some instances resulting in high rates of mortality. Some participants described a need for 
community detoxification ‘in the real world’ and observed the small success rates recorded in inpatient 
settings.   
‘Methadone is not compulsory. I don’t detox them. I facilitate their detox. I say that we cannot 
detox you, but you can detox yourself. I cannot control your detox. I can control your 
increase, but not your decrease. The only person who can detox is the patient themselves.’ 
Participant 4 
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‘Giving someone a gradual and supportive detox as they demand it, with as much aftercare 
support as they can is ideal. I rarely use in patient detox units because I do not trust them.’ 
Participant 7 
Several participants described experiences of patient self detoxification at home, and observed how 
improved community detoxification protocols were effective in providing supports for both methadone and 
benzodiazepine. Despite this, many instances of home detoxification led to opiate cravings and 
withdrawals, with many patients recommencing heroin, alcohol and other drug use. Underlying mental 
health issues were also observed to further complicate safe home detoxification.   
‘I would say that the majority of patients have done this at some stage, especially when 
someone become stable and just take methadone. A lot of patients do try and detox 
themselves, people forget there are physical and psychological components to addiction, 
they may get over the physical withdrawals within a day, it’s the psychological issues such 
as triggers that can lead to problems.’ Participant 3 
Participants underscored the need for improved aftercare ‘safety nets’ supports for both residential 
detoxification and community detoxification.  
‘There is a community detox programme in this area. The community detox protocols are 
very positive and progressive, and working closely with our colleagues is the only way 
forward.’  Participant 3 
‘I am increasingly conscious of the huge benefits and necessity to do residential aftercare 
following their detox to learn and prepare them with life without drugs and reduce the risk of 
relapse.’ Participant 7 
 
All participants were of the view that shared care treatment approaches in Ireland were much needed and 
essential.  Others described the difficulties of classification as Level 1 or Level 2 as difficult to implement 
in practice, and particularly given the nature of relapse where unstable patients necessitate greater levels 
of support within an interagency support network.   
‘The theoretical concept of Level 1 and Level 2 is excellent, but the practical implementation 
is a totally different story. The clinics do need to concentrate on chaotic patients, these 
patients should be treated in controlled environment, until they have become stable and then 
passed onto the community GP's. Drug users by their nature are unpredictable, even the 
ones who are stable can suddenly become unstable and when the patient becomes 
unstable, then the community GP will not have the time to work with the patient.’ Participant 
1 
Some participants described the need for universal and all encompassing treatment services and the 
need for a shift away from strict MMT and toward community based treatment for alcohol, opiate and 
mental health. This could potentially increase treatment uptake and remove the stigma attached to clinics. 
Several participants described the need for alternative forms of opiate substitution treatment such as 
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buprenorphine, the need for specialized in patient stabilisation, in patient benzodiazepine detoxification, 
and support structures for those with underlying psychiatric conditions. 
‘There are reasonable services for treating the heroin dependency medically, but all the 
other support services are sadly lacking, and there is not enough co ordination and cohesion 
between the two. I think the medical model seems to run separately to the other models and 
that’s a big problem.’ Participant 2 
However, several voided concerns around community service competencies, level of staff training in the 
area, and service philosophies around harm reduction versus abstinence, and issues around patient 
confidentiality.   
‘It’s essential, we have these barriers that are thrown up all the time, one of which is 
insurance and the second one is medical confidentiality, we are constantly told, we cannot 
share information with community treatment programmes and other rehab programmes, that 
is rubbish, if the patient agrees and signs a form and saying yes I want these people 
included in my care, you have the freedom to share the information.’ Participant 7 
‘In hindsight, we got a awful lot of things wrong, we should have been looking at a model of 
community pharmacies and small clinics, we need to normalize the treatment and make it as 
small as part of the patients life.’ Participant 4 
Several comments were made with regard to service rigidness with regard to patients needs (i.e. location, 
opening times), and the need for development of community nurse prescribers with minor input from 
doctors.   
‘Because only doctors can prescribe it, that tends to cause a barrier because a lot of doctors 
hide behind the fact, that they can only that can prescribe it, and it creates a wedge between 
them and other services that are in touch with service users. I do think it’s too elitist, though I 
don’t think it should just be doctors prescribing, there are some very good skills people with 
expertise who could easily prescribe this medication.’ Participant 15 
‘I personally believe that methadone prescribing is a technical task, it’s very, very simple and 
very easy. There is no great scientific or other knowledge required to prescribe methadone. 
My thoughts are that methadone prescribing would be better done by nurses and probably 
should be done by nurses, and that the doctors will have a role of overseeing the treatment 
and providing for primary care more so.’ Participant 16 
All participants observed issues relating to minors presenting with opiate dependency, and highlighted the 
need for specialised inpatient detoxification services without the need for parental consent and 
substitution pathways involving a multi disciplinary youth centred approach. Many concerns were raised 
with regard to adolescent treatment readiness and environmental factors needing psycho social 
intervention.   
‘They are a difficult group to treat because of the whole adolescent thing.  They are not 
children and they are not adults, and they are quite irrational and unreasonable at times, the 
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same issues apply if you have a 16 yr old who is injecting heroin four times a day, there is no 
question that he is better off on methadone.’ Participant 4 
 
Theme Six: MMT Training needs  
Several participants were happy with MMT training levels at the time of the research, and indicated 
no further training needs. Some comments were made about the lack of formal training in the 
addiction field for doctors in clinics and community practice, and the failure of the ICGP to provide 
adequate training, practitioner networking, evidence based protocols, and CMEs.   
‘New people coming in, might not realise that the top dose of 80mls is nonsense, there is no 
programme of training other than online, nobody gets to hear others views’. Participant 8 
‘It’s bad, the training is awful, the guidelines, they have failed miserably in training GP's.  A 
lot of the training need to be scrutinised, it’s not evidenced based and it is damaging to have 
something that has poor evidence.  We should have something similar to the NICE 
guidelines in the UK and these have been produced by experts.’  Participant 15 
A minority of participants working in private practice described feeling isolated and a need to meet and 
network with practitioners in clinics in order to update and consult around MMT issues. Supports for 
clinical practitioners were described as very good.  
‘The GPs like myself who don’t work in clinics have no opportunity to meet, there seems to 
be a policy for isolating us and making sure we do not meet. We are not allowed to know 
each other’s names.  In the long run, it cannot be conducive to good practice or consistent 
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Chapter 4. Discussion 
 
Qualitative research on doctor experiences of MMT remains scant, with most research efforts 
concentrating on patients overall life functioning and addiction treatment pathways. The research 
presents a ‘snapshot’ of participant observations and perspectives on MMT obtained from a convenience 
sample of participating docotors, and cannot be generalised or viewed as representative of all methadone 
prescribing doctors in Ireland.   
 
All participants were of the view that shared care treatment approaches in Ireland were much needed and 
essential. Some participants described the need for universal and all encompassing treatment services 
and the need for a shift away from strict MMT clinics and toward community based treatment for alcohol, 
opiate and mental health. Indeed, contemporary research underscores the need for long term and multi 
component treatment modalities for opiate dependence which include pharmacological, psycho-social 
rehabilitation and relapse prevention interventions (World Health Organisation, 2009). The findings 
highlight the need for continued development of community detoxification initiatives for both methadone 
and benzodiazepines (Progression Routes Initiative, 2011a;b). An effective treatment system for drug and 
alcohol dependence requires the availability of inpatient and community based detoxification to 
individuals, in the context of provision of managed withdrawal (Gowing et al., 2000a;b). However, 
concerns around community service competencies, level of staff training in the area, and service 
philosophies around harm reduction, and abstinence, and patient confidentiality were observed. The need 
for governmental consideration of alternative forms of opiate substitution treatment such as 
buprenorphine, the need for specialised in patient stabilisation in patient benzodiazepine detoxification, 
and support structures for those with underlying psychiatric conditions were reported. Comments were 
also made with regard to development of nurse prescribers and support staff roles in MMT provision. The 
lack of specific alcohol treatment pathways and adjunct counseling services for MMT patients was 
underscored.  All participants observed issues relating to minors presenting with opiate dependency, and 
highlighted the need for specialised inpatient detoxification services without the need for parental consent 
and substitution pathways involving a multi disciplinary approach.  Many concerns were raised with 
regard to adolescent treatment readiness and environmental factors needing psycho social intervention.   
 
A minority of participants working in private practice described feeling isolated and a need to meet and 
network with practitioners in clinics in order to update and consult around MMT issues. Research on 
general practitioner roles also call for expansion of roles into other health services, and continued 
professional development (Wynne-Jones et al., 2010). The same could be said for MMT training, 
certification and supports within a shared care system. Supports for clinical practitioners were described 
as very good. Several participants were happy with training levels at the time of the research, and 
indicated no further training needs. However, some comments were made about the lack of formal 
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addiction training for doctors in clinics or community practice, and the failure of the ICGP to provide 
adequate training, practitioner networking, CMEs and evidence based guidelines for MMT provision. 
Research on MMT has highlighted continued general practitioners' training needs in this area (Ford and 
Ryrie, 2000; Gabbay et al., 2001; Strang et al., 2004; Delargy 2008;). Observations were made with 
regard to new inexperienced prescribing doctors. However, it is encouraging to see that newly qualified 
doctors generally report greater acceptance of problematic drug users, and willingness to treat drug 
dependencies (Glantz and Taylor, 1986; Roche et al., 1991; Carnwath et al., 1999). It remains of 
paramount importance, as is evident in this research, that the recruitment of sympathetic doctors with 
positive attitudes towards helping those with drug dependence is vital (Bennet and Wright 1986b, Gabbay 
et al., 1996; Hindler et aL 1996; Abouyanni et al 2000; Kelly and Westerhoff, 2010).  
 
Of interest is that participant observations around MMT observed its effectiveness in reducing a range of 
patient harms in the form of injecting drug use, continued opiate use, transmission of BBVs, and 
stimulating recovery processes. Indeed, research findings consistently indicate MMTs effectiveness in 
reducing drug use and risk activities such as needle sharing, improving health outcomes and reducing 
mortality, its cost effectiveness, its ability to reduce criminal activity, and stimulate social, educational and 
employment engagement (Corsi et al., 2002; Sheerin et al., 2004; Teesson et al., 2006; Simoens et al., 
2006; Gowing et al., 2006; Mattick et al., 2009). Also of interest, were participant observations around 
inability to screen for frequent versus occasional heroin use, and injecting versus smoking opiate users 
for those on MMT. Negative service and community opinions around MMT were mentioned by some 
participants, and were centred on its substitution of one drug for another, and its conflict with abstinence 
focused treatment ideals (Joseph et al., 2000; Bell et al., 2002; Vigilant, 2004).  Studies do show that 
MMT programmes differ in terms of clinical practices (Stewart et al., 2003), and objectives which range 
from harm reduction (Roe, 2005), to long term maintenance (Ball and Ross, 1991) to abstinence from all 
drugs (Gossop et al., 2001). The need for a combined approach by utilising harm reduction such as 
methadone maintenance in conjunction with abstinence based approaches to treatment has been 
extensively proposed (Broekaert and Vanderplasschen, 2003; McKeganey et al., 2004; McKeganey, 
2005).  
 
Despite reporting very positive outcomes in providing the former addict with opportunity to recommence 
and lead a (semi) normal day to day life, participants observed how MMT restricted their patients’ 
freedom. Leaver et al., (1992) in their study of intravenous heroin users in MMT, reported on the greater 
numbers of routine consultations, emergency appointments to secure methadone, missed appointments 
and prescribed items in comparison with control subjects attending general practice, and indicated that 
intravenous heroin users utilised general practice to a greater extent that non drug users. This restriction 
of patient freedom and anxieties around chronic dependence is present in many studies on MMT 
(McKeganey et al., 2004; Holt, 2007), despite the correlation between longer treatment duration, 
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stabilisation and improved psycho-social outcomes, with reduced morbidity, poly drug use and crime 
involvement (Winstock et al., 2011). Research by Leaver et al., (1992) reported that the prescription and 
collection of methadone is responsible for greater numbers of patient visits. Structural factors relating to 
MMT create conditions for such premature treatment exit, and include daily collections of methadone, 
supervised consumption and urine analysis, clinic sanctioning of ‘dirty screens’ , restricted ‘takeaways’, 
client discomfort in pharmacy settings and impact on day to day freedom (Reisinger et al., 2009; Mancino 
et al., 2010; Harris and McElrath, 2012).  Despite these favourable outcomes in the reduction of opiate 
use and harmful routes of administration, participants also observed problematic issues relating to long 
term MMT, the tapering of methadone, and patient destabilisation. Similar findings are reiterated in the 
methadone research base (Bell et al., 2006; Coviello et al., 2011).  
 
Of note, is that although participants observed being restricted to methadone prescribing, many described 
providing their patients with a range of psychosocial supports within a positive, supportive and patient 
centred approach. In some instances, participants described knowing their patients much better, than the 
patients’ main permanent general practitioner consulted for general health conditions. Research shows 
that MMT patients often consult their permanent general practitioner for medical issues, whilst undergoing 
treatment for drug dependency in other practices and clinic settings (Leaver et al., 1992). This was 
observed to occur in order to preserve confidentiality. It is evident from the research that participants 
cared deeply for their MMT patients, and acted beyond their remit as prescribing doctor by providing 
crucial social support. Wynne-Jones et al., (2010) underscore the presence of both conflict between 
patient and GP, and between all stakeholders, and described the role responsibility of GPs as centred 
within a multiplicity of roles the GP is expected to play. Von Knorring et al., (2008) have reported on 
difficulties for GPs in leading ‘dual roles’ as patient advocate, medical expert, and gatekeeper. All 
participants observed patient centred and supportive views of MMT patients, which contributed to patient 
empowerment and self actualisation toward recovery.  
 
No participants described their MMT patients as any different to other patients attending their practice, 
with some participants describing MMT patients as problematic. At times and depending on client 
stabilisation, relations were compromised by instances of mistrust and loss of respect, with participants 
undertaking a policing role. Indeed, some research has observed that due to the nature of addiction, MMT 
clients are often not treated as patients, but rather as suspects (Vigilant, 2001; De Leon, 2000; Butler, 
2002; Luty and Grewal, 2002; Saris, 2008). Research commentaries have been made around 
‘dysfunctional consultations’ in MMT (Gabbay et al., 1999). Research has shown that GP attitudes can be 
negative toward opiate dependent patients due to manipulative, aggressive and chaotic type behaviours, 
and incur fluctuating levels of motivation impacting on the GP patient therapeutic alliance (Gruer et al., 
1997, Gabbay et al., 2001; Butler, 2002). In this way, despite the presence of potent doctor patient 
collaborative relations, these relationships between doctor and MMT patients were described as not quite 
Prescribing Doctor attitudes, experiences and perspectives on the provision of methadone 
maintenance treatment in Dublin. Van Hout and Bingham 
 22 
fitting into the normal doctor patient consultation due to the control of a prescribed drug, the level of 
contact between individuals on a weekly basis, and utilisation of urine screening. The disparity between 
medical service provider and client experiences is evident in the current literature base with medical 
supervision of opiate dependence promoting treatment retention, in contrast to patients requesting 
treatment completion (Winstock et al., 2011). 
 
Continued dialogue between doctor and patients was viewed as paramount in reducing harm, despite 
instances of destabilization and chaotic drug taking patterns. Indeed, patient centred medicine by 
consideration of patients’ knowledge, feelings, experiences, aspirations and desires is positively 
associated with patient satisfaction and improved patient outcomes (Nettleton, 1995; Steward, 1995; May 
and Mead, 1999; Kennedy, 2003). Despite the best efforts of prescribing doctors in the research to 
undertake shared decision making, on some level the doctor patient relationship remained doctor centred, 
by the very virtue of methadone prescribing. Participants were described as controlling the starting dose, 
and the rate of increase, with patients controlling a slow tapering and final detoxification under GP 
supervision and advice. Participants observed that levels of methadone dosage were dictated by the 
patient’s wishes with support from prior doctor-patient collaborative work within the therapeutic alliance.  
Methadone dosage appeared to be dictated by level of stabilisation and patient progress, attempts to 
secure placing in local CE schemes and therapeutic alliance between the doctor and patient. Several 
participants described how their patients were fearful of heroin withdrawals, and how this manifested in a 
phobic fear of reducing methadone down to too low a dose. Lintzeris et al., (2007) has described patient 
fear of remaining on methadone as contributing to attempts of clients to avoid higher doses of 
methadone, and attempting to seek out short term treatment modalities, despite research showing that 
longer duration treatment, and higher methadone dosage along with psychosocial intervention is 
associated with improved addiction and psychosocial outcomes (Sees et al., 2000; Kakko et al., 2003; 
Gerra et al., 2003; Mattick et al., 2009). Fear of methadone detoxification is reiterated in the research 
(Leaver et al., 1992; Van Hout and Bingham, 2011; McDonnell and Van Hout, 2010; 2011). 
 
MMT has a well established ability to reduce opiate overdose fatalities by stabilising the addicts lifestyle, 
and reducing poly drug use and harms associated with intravenous use (hepatitis and HIV) (World Health 
Organisation, 2004). Continued use of other drugs and alcohol can occur, as methadone does not have a 
specific pharmacological effect on non-opioid drug use (Schuckit, 2006; Cox et al., 2007; Kelly et al., 
2009). Research by Bennett and Wright (1986) reported on the high rates of continued illicit drug use 
among methadone attendees. Other researchers comment on the need for research on methadone 
diversion and factors implicated in enabling or reducing this behaviour, within the context of supportive 
MMT therapeutic relations (Gabbay et al., 1999). Poly drug use whilst engaging in MMT was mentioned 
by several participants, and included alcohol and drugs such as cocaine, cannabis, amphetamine, 
ecstasy, anti anxiety medication, new psychoactive substances (such as mephedrone) and heroin.  In 
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particular, the emergence of mephedrone and other synthetic stimulants was observed to create 
difficulties, due to the lack of available screening mechanisms and clinical information available. 
Research has highlighted that clinical research on emergent new psycho active substances is scant (LGC 
Standards, 2010; Long, 2010; Pillay and Kelly, 2010; Van Hout and Brennan, 2011; Van Hout and 
Bingham, 2012).  Research commentaries show that abstinence based models MMT incurs greater rates 
on poly drug use (Caplehorn et al., 1996; Caplehorn et al., 1998). Participant views on continued drug 
and alcohol use whilst in MMT were mixed, with some participants accepting of continued licit and illicit 
drug use whilst on methadone, and others strongly opposed to supplying methadone (particularly 
takeaways) in these circumstances. They described dealing with positive opiate urine screens by 
increasing methadone dosage to try and keep patients from using heroin, probing their patients about 
discontinuing the programme, and working towards a harm reduction dose. In many cases, MMT patients 
reduced and ceased heroin use over time. The majority of participants stated that excessive alcohol 
consumption, and alcohol dependency was common amongst their patients, observed that problematic 
alcohol use was difficult (and in some practices impossible) to screen for, and appeared restricted to the 
substitution treatment of opiate dependence via MMT. In addition, benzodiazepine dependence also 
contributed to problems in MMT.   
 
Self detoxification attempts are frequent in opiate dependent populations (Noble et al., 2002; Dennis et al 
2005; Hopkins and Clark, 2005; Ison et al., 2006), with a majority of opiate dependents remaining on the 
periphery of treatment systems (Friedman et al., 2004; Bobrova et al., 2006; 2007; Petersen et al., 2010; 
McDonnell and Van Hout, 2010; 2011). Mixed feelings were recorded with some participants describing a 
reluctance to encourage full detoxification, due to the high rates of relapse, and others encouraging 
patient detoxification. In all instances, client requests to reduce or increase methadone were heard and 
facilitated within a supportive patient led approach, and when stable social circumstances such as 
housing were in place. This was done in order to avoid potential overdose and destabilisation. All 
participants described instances of successful patient detoxification from methadone, but also observed 
patients reducing to 40mls or less, and then destabilizing. The revolving door of relapse and MMT uptake 
was common, particularly among young dependents attempting fast reduction of methadone, in some 
instances resulting in high rates of mortality. Research indicates that between on average 40 and 60% of 
MMT patients drop out of treatment within 12 to 14 months with relapse to heroin use (Nosyk et al., 
2010). However, research shows that detoxification and the achievement of abstinence is possible 
without formal treatment (Ward et al., 1999, Bobrova et al., 2006, Ison et al., 2006, Bobrova et al., 2007), 
and is often preferred with community based supports from local GPs, family and other users (Hartnoll, 
1992, McElrath, 2001a; b, Appel et al., 2004, Hopkins and Clark, 2005, Grella et al., 2009).   
 
The majority of participants observed difficulties in the prescribing of methadone as per the national 
Methadone Protocols advised by the methadone implementation protocol committee, and described this 
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scenario as 'big brother looking over you’.  Participants highlighted the need to measure MMT in relation 
to its outcomes, and not the MMT process as advocated by the Methadone Protocols. Several 
participants described the methadone protocols as a policing system rather than therapeutic intervention 
for opiate dependents, with little evidence consulted in the design of specified guidelines or the evaluation 
of individual outcomes. It is evident that MMT outcomes are dependent on timely treatment entry, 
adequate medication dosage, duration, support and continuity of treatment, levels of engagement in 
concurrent counseling and presence of cohesive support networks of adjunctive medical, social and 
community services, and successful detoxification (World Health Organisation, 2009). Issues in the 
auditing of prescribing doctors, doctor adherence and non adherence to the protocols, variation in doctor 
approaches to MMT, and levels of patient centredness in the MMT treatment pathway were mentioned. 
Wynne-Jones et al (2010) identify such barriers to good general practice both within and outside of the 
healthcare system. The requirement for regular urine screening was observed by most participants to be 
degrading and unnecessary.  The management of methadone prescribing was observed to be restrictive 
and related to the 7 day methadone prescription pads provided by the Methadone Protocol, and observed 
to contribute to patient institutionalisation, and in some instances unequal power differentials between 
doctor and patient.  The Methadone Protocols appeared to place unnecessary and unwanted restrictions 
on their freedom to prescribe as normal GP, particularly in the case of prescribing doctors placed in 
addiction clinic settings, as opposed to doctors operating in general practice. Several participants 
described ignoring the methadone protocols or not reading them. Regulations around Level 1 and Level 2 
patient numbers also appeared to restrict numbers of treatment places.  Participants described the 
difficulties of classification as Level 1 or Level 2 as difficult to implement in practice, and particularly given 
the nature of relapse where unstable patients necessitate greater levels of support within an interagency 















Prescribing Doctor attitudes, experiences and perspectives on the provision of methadone 
maintenance treatment in Dublin. Van Hout and Bingham 
 25 
Chapter 5. Conclusion 
 
The research, however small scale, exploratory and confined to a convenience sample of methadone 
prescribing doctors in the Dublin area, represents an important description of prescribing doctors 
experiences of MMT and their relationships with their patients. . The researchers wish to sincerely thank 
the participants for their involvement in the research, and recognise that the findings cannot be 
representational of all prescribing doctors in Ireland Observations around MMT were positive in both 
reducing harm and presenting an important turning point for opiate dependents. It is important to 
underscore that doctor efforts to assist their MMT clients were grounded in positive, empathic 
relationships with their patients, and in many cases surpassed their roles as methadone prescribers. 
Concerns are evident with regard to the impact of the National Methadone Protocols, on two levels, 
namely the preoccupation with the methadone prescribing process as opposed to MMT patient outcomes, 
and the restrictions imposed on both Level 1 doctors, and the number of resulting treatment places 
available. Policy makers would be advised to consider the expansion of MMT provision to include 
alternative substitution drugs, improved interagency community based psychosocial supports, treatment 
for poly drug and alcohol use, and the development of a network of community nurse prescribers.  
Concerns remain in the form of alcohol and poly drug taking, and pervasiveness of benzodiazepine 
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Information about the Research and Informed Consent Statement  
You are invited to participate in a qualitative study that seeks to learn more about your experiences as 
General Practitioner involved in the provision of methadone maintenance treatment for clients resident in 
the Dublin area.  Research consistently highlights general practitioners' training needs in this area, 
alongside efforts to reduce health professional negative stereotypical opinions and attitudes toward 
problematic drug users.   
 
The research builds on an earlier study in the Dublin North East area which underscored the need for 
improved doctor and service user consultative relations in MMT (Van Hout and Bingham, 2011).  We wish 
to explore prescribing doctor attitudes, experiences and opinions toward methadone maintenance 
treatment in the Dublin area.   
 
Methods 
Ethical approval for the study was granted by Waterford Institute of Technology in October 2011.  The 
methodologies were conducted in accordance to standards set by the European Monitoring Centre for 
Drugs and Drug Addiction, and the research protocol of the National Advisory Committee on Drugs.  
General ethical principles of the Economic and Social Research Council were also adhered to throughout 
all research phases [ESRC Research Ethics Framework: 22-26]. 
 
I (Tim Bingham) am the researcher and I will be interviewing people for this study.   
 
The interview will last about 1 hour.  I am not collecting names or other personal identifiers – people’s 
identities will remain anonymous. Your participation in this study is voluntary.  You can withdraw from the 
interview at any time.  If any criminal activity is disclosed during the course of the interviews, I will 
encourage you to report this.  
 
I am asking for your consent for us to tape the interview.  If you are uncomfortable with having the 
interview taped, you can say so and I will take notes during the interview.  If names appear in the tape, I 
will omit this information shortly after the interview.  I will transcribe the tapes shortly after an interview is 
completed and I (Dr Marie Claire Van Hout) am the only person who will have access to the tapes which 
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will be in a locked cabinet.  The tapes will be destroyed post transcription.  The transcribed narratives will 
be stored on a password protected computer at Waterford Institute of Technology.  Once all the 
interviews are completed and transcribed, I will write a report for the DNEDTF.   
 
I have received ethical approval for this study from Waterford Institute of Technology in the South East of 






I consent to participating in an interview  _______________    _______________ 
         Mark      Date 
I consent to having the interview taped  _______________    _______________ 
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Interview Guide 
 Are you a level 1 or 2 prescribing doctor?  
 What is your perception and knowledge of problematic alcohol and drug use in the area where your 
practice is located?  
 Do you view drug dependency as a social or medical issue?  
 What is your opinion on methadone maintenance treatment (MMT)? 
 Can you describe your patient client relationships with methadone maintenance clients?  
 Can you describe any issues regarding methadone maintenance treatment (MMT) in your practice? 
 Are you confident in your ability to provide quality methadone maintenance treatment (MMT)?  
 What is your preferred course of action in relation to methadone dosage? 
 What is your preferred course of action when a client requests to reduce their dosage? 
 Have you assisted clients in detoxifying? If so can you describe these experiences? 
 Have you come across many instances of home detoxification?  
 What is your opinion on continued heroin and other drug use whilst on methadone maintenance 
treatment? 
 Do you prescribe anti anxiety medication to your patients on methadone maintenance treatment? 
 Does the current methadone protocols restrict your work with clients 
 What in your opinion is the best form of treatment for minors dependent on opiates? 
 Do you work closely with the local pharmacists? 
 What is your opinion on shared treatment care approaches? 
 Can you describe any gaps in treatment service supports? 
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